Key points are not available for this paper at this time.
Elranatamab is a humanized, bispecific antibody that targets B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells and CD3 on T cells, with the aim of inducing T cell-mediated cytolysis of the MM cells 1 , 2 . Elranatamab was approved as monotherapy for relapsed-refractory MM (RRMM) based on the phase II MagnetisMM-3 (NCT04649359) registrational study 3 . Here, we report clinical outcomes with standard-of-care elranatamab in a real-world RRMM population as part of the French compassionate use program.
Malard et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: